Skip to main content

Table 2 Comparison of different thrombophilic parameters of the studied groups

From: Thrombophilia in hepatocellular carcinoma

Variables Control group (N = 45) Cirrhotic patients (N = 70) HCC patients (N = 70) P value Post hoc analysis
PT (s) 12.5 ± 0.3 22.3 ± 5 20.9 ± 4.7 0.0000* P1 < 0.001
P2 < 0.001
P3 = 0.14
Prothrombin conc.% 88.7 ± 3.7 36.6 ± 17.6 39.7 ± 15 0.0000* P1 < 0.001
P2 < 0.001
P3 = 0.40
TT (s) 18.7 ± 1.41 19.9 ± 1.52 33.22 ± 13.62 0.0000* P1 = 0.73
P2 < 0.001
P3 < 0.001
APTT (s) 25.20 ± 3.2 27.53 ± 4.45 43.54 ± 18.53 0.0000* P1 = 0.55
P2 < 0.001
P3 < 0.001
Fbg (g/l) 2 (0–10) 2.5 (0–15) 10 (2–25) 0.0000*** P1 = 0.99
P2 < 0.001
P3 < 0.001
Protein C (%) 99.8 ± 26.3 49.7 ± 12.5 54.5 ± 15.3 0.0000* P1 < 0.001
P2 < 0.001
P3 = 0.24
Protein S (%) 85.6 ± 20.4 61.8 ± 10.2 59.2 ± 18.9 0.0000* P1 < 0.001
P2 < 0.001
P3 = 0.62
Antithrombin activity (%) 88.1 ± 10.4 49.7 ± 11.5 52.5 ± 9.7 0.0000* P1 < 0.001
P2 < 0.001
P3 = 0.26
Lipoprotein (a) (mg/l) 20 (2–40) 7 (2–14) 11 (2–30) 0.0000*** P1 < 0.001
P2 < 0.001
P3 = 0.074
Homocysteine (μmol/l) 12 (5–18) 15 (7–29) 26 (10–45) 0.0000*** P1 = 0.13
P2 < 0.001
P3 < 0.001
APCR (N (%)) 2 (4.4%) 6 (8.6%) 9 (12.9%) 0.3  
FVL mutation (N (%)) 1 (2.2%) 2 (2.8%) 4 (5.7%) 0.55  
  1. Values are expressed as the mean ± standard deviation (SD) while values of Fbg, lipoprotein (a), and homocysteine are given as the median and interquartile range (IQR)
  2. Significant difference (P value < 0.05)
  3. P1 control group vs cirrhotic patients, P2 control group vs HCC patients, P3 cirrhotic patients vs HCC patients, PT prothrombin time, TT thrombin time, APTT activated partial thromboplastin time, Fbg fibrinogen, APCR activated protein C resistance, FVL mutation factor V Leiden (FVL) mutation
  4. *ANOVA test
  5. ***Kruskal-Wallis test